Image For Activity Cover
GRACIOEM2302 - CME/CMLE - Resectable Non-Small Cell Lung Cancers: The Role of Biomarker Testing and Evaluation of Pathological Response Following Neoadjuvant Treatment
Course Description

Resectable Non-Small Cell Lung Cancers: The Role of Biomarker Testing and Evaluation of Pathological Response Following Neoadjuvant Treatment
 
This activity is designed to engage pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team in improving the diagnosis, biomarker testing, and treatment of patients with resectable non-small cell lung cancer.
Course topics include:

  • Roles of biomarker testing in resectable NSCLC
  • PD-L1
  • EGFR
  • ALK
  • Evaluation of posttreatment lung cancer resection specimens

Faculty/Authors
Chen Zhang, M.D., Ph.D
Associate Attending Pathologist, New York-Presbyterian Hospital
Associate Professor of Clinical Pathology and Laboratory Medicine
Weill Cornell Medical College, Cornell University 

Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
 
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning and Improvement

CME/CMLE Credit: 0.5
Estimated Completion Time: 0.5 hour
Format: Online educational activity

Credit Designation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
 
The ASCP designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
 
ASCP designates this activity for a maximum of 0.5 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.
 
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time

Method of Participation
To complete the activity and receive credit, the participant must complete the online activity. CME certificates will be provided online.
 
Commercial Support
This activity is funded by an independent educational grant from Bristol Myers Squibb.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Content and click the first module of the course.
  3. Complete the Demographic Survey.
  4. Complete the Pre-Test.
  5. Review the Educational Activity.
  6. Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
  7. Submit the course Evaluation.
  8. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures 

Technical Considerations 

Release Dates: 11/1/2023
Review Date:
Expiration Date: 11/1/2026 




Course Objectives

Upon completion of this activity, you will be able to:

  • Discuss the critical roles of biomarker testing in patients with resectable NSCLC per NCCN treatment guidelines

  • Review the updated methods of choice for appropriate biomarker testing for NSCLC

  • Describe best practices for specimen collection and handling to ensure the accurate evaluation of pathological response

  • Utilize established post-neoadjuvent chemo-immunotherapy-related pathological response scoring systems to assess pathological response in patients with resectable NSCLC

 
Summary
Availability: On-Demand
Credit Offered:
0.5 CME/CMLE Credit
Powered By